It is crucial to determine quickly whether a patient is suffering from a bacterium or a virus, as the treatment protocols are quite different. For a doctor to treat the patient quickly and correctly, he/she needs to know precisely what the pathogen is…and Encore Holdings’ affiliated labs’ tests help with just that: They diagnose the pathogen quickly and correctly, enabling the physician to bring swift relief to his/her patient and potentially reduce the severity and duration of the illness.
This is because our respiratory pathogen panels are accomplished with molecular testing, which is appreciably superior to the screening doctors have traditionally used. Screen testing is dependent not only on proper physician collection and preparation but on the patient having a large quantity of virus or bacteria present. Screen testing often falls prey to both false positives and false negatives and has a failure rate that can be as high as 69 percent. Furthermore, with influenza, screen testing will not inform the physician as to which species of the flu a patient has. Molecular testing will tell him/her that
Molecular testing also compares strongly with the typical, standard conventional culture and sensitivity testing. The latter can take from a few days up to a full week for test results and requires a live organism sampling. Molecular testing results take just 24 hours, and the test does not require live organisms.
Our RPP panel utilizes PCR (Polymerase Chain Reaction), which expands the limits of detection from those of conventional tests and can differentiate 19 strains of respiratory viruses and three bacterial species including community-acquired pneumonias and also Legionnaires’ Disease.